CECR6 Antibody - BSA Free
Novus Biologicals, part of Bio-Techne | Catalog # NBP2-82654
Key Product Details
Species Reactivity
Human
Applications
Western Blot
Label
Unconjugated
Antibody Source
Polyclonal Rabbit
Format
BSA Free
Concentration
0.5 mg/ml
Product Specifications
Immunogen
The immunogen is a synthetic peptide directed towards the N terminal region of human CECR6. Peptide sequence: STGAEREDDDESLSVSKPLVPNAALLGPPAQVGAPAGPAPVAFSSSAATS The peptide sequence for this immunogen was taken from within the described region.
Clonality
Polyclonal
Host
Rabbit
Description
Novus Biologicals Rabbit CECR6 Antibody - BSA Free (NBP2-82654) is a polyclonal antibody validated for use in WB. All Novus Biologicals antibodies are covered by our 100% guarantee.
Scientific Data Images for CECR6 Antibody - BSA Free
![Western Blot: CECR6 Antibody [NBP2-82654]](https://resources.bio-techne.com/images/products/CECR6-Antibody-Western-Blot-NBP2-82654-img0001.jpg "Western Blot: CECR6 Antibody [NBP2-82654]")
Western Blot: CECR6 Antibody [NBP2-82654]
Western Blot: CECR6 Antibody [NBP2-82654] - WB Suggested Anti-CECR6 Antibody Titration: 0.2-1 ug/ml. ELISA Titer: 1:312500. Positive Control: HT1080 cell lysateApplications for CECR6 Antibody - BSA Free
Application
Recommended Usage
Western Blot
1.0 ug/ml
Formulation, Preparation, and Storage
Purification
Affinity purified
Formulation
PBS, 2% Sucrose
Format
BSA Free
Preservative
0.09% Sodium Azide
Concentration
0.5 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Background: CECR6
Alternate Names
Cat Eye Syndrome Chromosome Region, Candidate 6
Gene Symbol
CECR6
Additional CECR6 Products
Product Specific Notices for CECR6 Antibody - BSA Free
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...